These studies collectively demonstrate that AAV-based gene therapy strategies, whether through U7snRNA to interfere with CUG repeat sequences or through the CRISPR Cas13 system to degrade DMPK mRNA, can effectively improve the molecular and functional characteristics of DM1. The gene discussed is DMPK; the disease is myotonic dystrophy type 1.